Miller Global Investments LLC Buys Shares of 7,716 Astrazeneca Plc $AZN

Key Points

• Miller Global Investments LLC purchased a new position of 7,716 shares in Astrazeneca (NYSE:AZN) in the fourth quarter, valued at approximately $709,000.
• Astrazeneca declared a dividend of $1.595 per share payable on March 23 (record/ex-dividend date February 20); the article reports a yield of 156.0% and a payout ratio of 66.26%.
• Analyst coverage shows nine Buys and one Sell, giving Astrazeneca a consensus rating of "Moderate Buy" with an average price target of $95.75.

Miller Global Investments LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 7,716 shares of the company's stock, valued at approximately $709,000.

Several other hedge funds also recently made changes to their positions in the business. Binnacle Investments Inc lifted its position in shares of Astrazeneca by 21.8% in the third quarter. Binnacle Investments Inc now owns 660 shares of the company's stock worth $51,000 after purchasing an additional 118 shares in the last quarter. Chapin Davis Inc. grew its position in Astrazeneca by 3.3% in the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company's stock valued at $291,000 after purchasing an additional 120 shares in the last quarter. 44 Wealth Management LLC increased its stake in Astrazeneca by 0.7% in the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company's stock valued at $1,283,000 after buying an additional 124 shares during the last quarter. CoreCap Advisors LLC increased its stake in Astrazeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company's stock valued at $41,000 after buying an additional 125 shares during the last quarter. Finally, Highline Wealth Partners LLC lifted its position in Astrazeneca by 32.0% during the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company's stock worth $41,000 after buying an additional 129 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Performance

Shares of AZN stock opened at $188.76 on Friday. Astrazeneca Plc has a 12-month low of $122.48 and a 12-month high of $212.71. The company has a market cap of $292.75 billion, a price-to-earnings ratio of 28.82, a P/E/G ratio of 1.42 and a beta of 0.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. Astrazeneca's dividend payout ratio (DPR) is presently 66.26%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AZN. Morgan Stanley restated an "overweight" rating and set a $103.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 3rd. Barclays reaffirmed an "overweight" rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Weiss Ratings initiated coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a "buy (b)" rating for the company. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Astrazeneca in a research note on Friday, February 6th. Finally, Citigroup assumed coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a "buy" rating on the stock. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Astrazeneca has a consensus rating of "Moderate Buy" and an average price target of $95.75.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.